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Abstract
AIM: To evaluate the effectiveness of thiopurines in 
maintaining steroid-free remission in routine clinical 
practice.
METHODS: The multi-center Pediatric Inflammatory 
Bowel Disease Network (PIBDNet) cohort study pro-
spectively collected data on thiopurine naïve patients 
initiating mercaptopurine (6MP) or azathioprine. Pa-
tients with a diagnosis of Crohn’s disease (CD) were 
included in our study upon entering remission as de-
termined by physician global assessment (PGA) within 
365 d of initiation of thiopurines. The primary outcome 
of the study was maintenance of steroid-free remission 
(SFR) at each follow up visit. Patients were considered 
treatment failures if there had been a change in PGA 
from remission to mild, moderate or severe disease; 
disease relapse between visits; need for rescue therapy 
(biologic therapy, methotrexate, steroids); thiopurine 
discontinuation, hospitalization or surgical interven-
tion. A secondary outcome defined treatment failure as 
a change from remission to moderate or severe (not 
mild) in addition to the previously defined criteria.
RESULTS: Sixty-five of 182 patients in the PIBDNet 
registry met criteria for inclusion in this study. Forty-
five of 65 (69%) of included patients achieved re-
mission within 180 d of thiopurine initiation. For the 
primary outcome, 47% and 23% of patients remained 
in SFR at 6 and 12 mo. The mean thiopurine dose at 
initiation for the 65 included patients was 0.89 ± 0.31 
mg/kg per day. Metabolite levels were obtained in 48% 
(31/65) of the included patients with a mean 6TG level 
of 258 pmole/8 × 108 RBC ± 147. For the secondary 
outcome, 65% and 42% of patients remained in SFR 
at 6 and 12 mo.
CONCLUSION: Thiopurines were less effective in main-
taining remission for pediatric CD in this “real world” 
cohort than has been previously described. Variation 
in thiopurine dosing and metabolite measurement was 
found among practitioners.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This manuscript describes the real world ef-
fectiveness of thiopurines in maintaining remission for 
pediatric Crohn’s disease. The outcomes differ in com-
parison to the initially published randomized controlled 
trial for pediatric Crohn’s but are similar to more re-
cently published studies evaluating the effectiveness of 
thiopurines. The study evaluates data from a pediatric 
inflammatory bowel disease registry and is representa-
tive of real world clinical care. Varitation in practitioner 
approach to thiopurine dosage and metabolite mea-
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surement was found. Implementation of a more stan-
dardized approach to use of thiopurines could impact 
clinical outcomes.
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INTRODUCTION
The incidence of  pediatric Crohn’s disease (CD) is in-
creasing and nearly 25% of  patients with inflammatory 
bowel disease (IBD) present during childhood[1-3]. Thio-
purines have been shown to be effective in the treatment 
of  children and adults with CD[4-6] and are associated 
with a steroid sparing effect[7]. However, studies describ-
ing the effectiveness in maintaining steroid-free remis-
sion (SFR) with thiopurines have been inconsistent[6-13]. 
The efficacy of  thiopurines was previously evaluated by 
a randomized controlled trial (RCT) in pediatric patients 
with moderate to severe CD. This study found that 
greater than 90% of  patients achieving clinical remission 
remained in clinical remission for 18 mo[7]. Subsequent 
retrospective pediatric studies have found thiopurines to 
be less effective than the initial RCT[14,15], as has the more 
recent SONIC trial performed in adults[16].
Variation in the delivery of  chronic illness care and 
its negative impact upon outcomes has been previously 
described[17]. Evaluation of  pediatric IBD registry data 
identified significant variation between care centers in 
the initial management of  patients with CD including 
the frequency of  thiopurine use, thiopurine dosing, and 
thiopurine methyl transferase (TPMT) measurement[18,19]. 
Efforts to reduce variation in pediatric IBD care using 
quality improvement methods have led to improved pa-
tient outcomes[20].
 The aim of  our study was to examine maintenance 
of  SFR in patients who achieved clinical remission after 
initiating thiopurine therapy. The multi-center Pediatric 
Inflammatory Bowel Disease Network (PIBDNet) pro-
spectively collected data on patients initiating thiopurine 
therapy, thus presenting an opportunity to investigate 
this research question using data from a large number of  
diverse clinical practices and care approaches representa-
tive of  real world clinical care.
MATERIALS AND METHODS
Study subjects
The PIBDNet multi-center cohort study prospectively col-
lected data from thiopurine naïve patients initiating mer-
captopurine (6MP) or azathioprine (AZA) therapy. Forty-
eight practice sites enrolled patients in the cohort study. 
Participating practitioners included pediatric gastroenterol-
ogists from both university and private practice settings of  
various sizes[19]. Evaluation of  data from patients enrolled 
from 2004-2008 was performed. Enrolled patients were 
aged 1-17 years with a diagnosis of  CD. Data was collected 
and recorded at initiation and each subsequent follow up 
visit. Disease activity was assessed by physician global as-
sessment (PGA) at the time of  the visit and categorized as 
inactive (remission), mild, moderate, or severe disease.
All patient management decisions were determined 
by each practitioner rather than a standardized proto-
col. Variations in practice approach among practitioners 
included thiopurine dosage, decisions about continuing 
thiopurines, timing or need to obtain 6MP metabolite 
levels, need for additional medications, and frequency of  
follow up visits.
Patients were included in this analysis if  clinical re-
mission by PGA had been achieved within 70-365 d 
from thiopurine initiation. This visit was considered 
time zero for this analysis. We restricted this analysis to 
patients achieving clinical remission between 70-365 d 
in order to isolate the effect of  thiopurine monotherapy. 
Seventy days was chosen a priori with the expectation 
that the therapeutic effect of  thiopurines would not have 
been achieved prior to 10 wk after initiation. Patients not 
achieving remission by 365 d after thiopurine initiation 
were considered non-responders and excluded.
Additional exclusion criteria for the primary analy-
sis were: inadequate follow up data (< 70 d of  follow 
up after thiopurine initiation or no follow up visit after 
achieving remission), current or previous treatment with 
infliximab, methotrexate (MTX), cyclosporine, or tacroli-
mus, heterozygote or homozygote mutant TPMT status, 
or patients who required surgical intervention prior to 
entering remission.
Study outcomes
After entering remission, each subsequent visit was evalu-
ated for maintenance of  SFR or treatment failure. In our 
primary analysis (analysis 1), treatment failure was defined 
as a change in PGA from remission to mild, moderate or 
severe; disease relapse recorded between visits; a need for 
rescue therapy [MTX, infliximab, cyclosporine, tacroli-
mus, corticosteroids (CS)]; thiopurine discontinuation; or 
hospitalization/surgical intervention after entering remis-
sion. Patients treated with CS upon entering remission 
who remained on CS for an additional 30 d were also 
considered treatment failures.
A secondary outcome considered a change in PGA 
from remission to moderate or severe disease (but not 
mild) as a treatment failure (analysis 2) in addition to the 
previously defined criteria for treatment failure in the 
primary analysis.
Exploratory analyses included patients with normal 
or heterozygote TPMT status that met inclusion criteria 
defined above. Primary and secondary outcomes for 
this combined cohort were performed using the above 
definitions for treatment failure to determine if  TPMT 
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Table 1  Demographics-primary analysis  n  (%)
status impacted maintenance of  remission.
Dose
Thiopurine dosage in mg/kg per day was determined 
at registry enrollment and upon entering remission and 
was expressed as dose of  6MP. For patients treated with 
AZA, a conversion factor of  dose in mg/2.07[21] was 
used to express medication dose as a 6MP equivalent. 
Dosing and decisions to obtain 6MP metabolites levels 
was determined by each practitioner and varied accord-
ing to their clinical practice.
Statistical analysis
Kaplan Meier survival curves evaluating maintenance of  
SFR were performed for each analysis described above. 
A comparison of  demographic data for included and ex-
cluded patients was performed using chi-square testing 




One hundred eighty-two patients were enrolled in the 
PIBDNet cohort. Sixty-five patients met inclusion crite-
ria for this analysis. Reasons for exclusion are shown in 
Figure 1. Demographic data including age, gender, dis-
ease duration, disease location, and disease activity at en-
rollment by PGA was similar for included and excluded 
patients (Table 1).
Study outcomes
For the primary outcome, 47% of  patients remained in 
SFR 6 mo after achieving remission (Figure 2-analysis 1). 
By 12 mo, 23% of  patients remained in SFR. Forty-five 
of  the 65 patients achieved remission between 70-180 d 
after thiopurine initiation. For this cohort, 51% and 28% 
maintained remission at 6 and 12 mo.
Patients could have multiple reasons for treatment 
failure. Thirty-eight patients had a change in PGA from 
remission to active disease. Fourteen patients required 
steroid therapy. Sixteen patients were lost to follow up 
within 12 mo of  study entry.
 For the secondary outcome in which a PGA of  mild 
was not considered a reason for treatment failure, we 
found that 65 % and 42 % of  patients remained in SFR 
at 6 and 12 mo (Figure 2-analysis 2). For the 45 patients 
achieving remission between 70-180 d, 67% and 47% 
maintained remission for this secondary outcome at 6 
and 12 mo.
The exploratory analysis included the 65 patients 
with normal TPMT status and 12 additional patients 
with heterozygote TPMT status (total n = 77) and found 
similar results: 45% and 26% of  patients remained in 
SFR for the primary outcome at 6 and 12 mo; 61% and 
42% of  patients remained in SFR for the secondary out-
come at 6 and 12 mo.
Dose
The mean dose in mg/kg per day (mean ± SD) at thio-
purine initiation for the 65 included patients was 0.89 
± 0.31 mg/kg per day compared to 1.06 ± 0.38 mg/kg 
per day for the 117 excluded patients (P = 0.002). The 
mean dose upon entering remission for the 65 included 
patients was 1.09 ± 0.33 mg/kg per day.
Metabolite levels
In total, 47% (86/182) of  patients had metabolite levels 
obtained. Thirty-one of  the 65 included patients had 
6TG levels [pmole/8 × 108 red blood cells (RBC)] ob-
tained with an mean level of  258 pmole/8 × 108 RBC ± 
147 [median 238 (range: 25-746)]. Of  the 117 patients 
excluded from study entry, 55 patients had 6TG levels 




      41 - failed to achieve remission
      40 - < 70 d of follow up or no follow up after entering remission
      18 - heterozygote TPMT
      16 - required surgical intervention, rescue medication or had
              missing data prior to entering remission
        2 - discontinued thiopurines prior to entering remission
Figure 1  Flowchart of patient inclusion for primary analysis. TPMT: Thio-
purine methyl transferase.
Included 
(n  = 65)
Excluded 
(n  = 117)
P  value
Age (yr) 12.98 ± 2.8 13.4 ± 2.9 NS
Gender
   Male 39 (60.0)   65 (55.6) NS
   Female 26 (40.0)   52 (44.4)
Disease duration
   < 12 mo
   > 12 mo 59 (90.7) 100 (85.5) NS
6 (9.2)   17 (14.5)
Race
   Caucasian 52 (80.0) 102 (87.2) NS
Disease location
   Upper 37 (56.9)   79 (67.5) NS
   Ileal 49 (75.4)   91 (77.9) NS
   Colonic 54 (83.1)   97 (82.9) NS
Thiopurine
   6MP 42 (64.6)   87 (77.0) NS
   AZA 23 (35.4)   26 (23.0)
PGA
   Remission   7 (10.8) 5 (4.4) NS
   Mild 22 (33.8)   41 (36.3)
   Moderate 31 (47.7)   58 (51.3)
   Severe 5 (7.7)   9 (8.0)
Mean initiation dosage
(mg/kg)     0.89 ± 0.31   1.06 ± 0.37 0.002
6TG level     258 ± 147   231 ± 161 NS
(pmole/8 × 108 RBC) (n = 31) (n = 55)
NS: No significant.
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with a mean of  231 pmole/8 × 108 RBC ± 161 [median 
195 (range: 29-965)]. This difference between included 
and excluded patients was not significant (P = 0.2).
DISCUSSION
Thiopurines are commonly used therapies for adult and 
pediatric patients with CD, having been shown to be 
effective for maintaining remission and providing a ste-
roid sparing effect. Our multi-center prospective study 
evaluating patients from diverse centers throughout 
the United States found that 47% and 23% of  patients 
maintained SFR at 6 and 12 mo; 65% and 42 % of  pa-
tients remained steroid free with a PGA of  either remis-
sion or mild disease at 6 and 12 mo respectively.
The effectiveness of  thiopurines in maintaining re-
mission in previous pediatric studies in CD has been 
mixed. The RCT evaluating children with moderate to 
severe CD found greater than 90% of  patients treated 
with steroid therapy and 6MP at diagnosis maintained 
disease remission through 18 mo[7]. Maintenance of  re-
mission in our study was comparatively reduced. Despite 
differences in study design (RCT vs prospective cohort 
study), methods of  assessing disease activity (Harvey-
Bradshaw index vs PGA), dosing variation and definition 
of  treatment failures between the studies, the differences 
in study outcomes warrant further consideration.
Our findings expand upon a growing body of  lit-
erature suggesting that the effectiveness of  thiopurines 
in routine clinical practice for pediatric CD is lower 
than might have been predicted from the initial RCT. A 
single-center, retrospective study found 60% and 40% 
of  pediatric patients with CD to maintain SFR at 6 and 
12 mo. Another small pediatric study evaluating patients 
with CD or UC treated with thiopurines found 30% SFR 
at 6 mo[14,15].
 The 2008 Cochrane review evaluating the mainte-
nance of  disease remission in adult patients with CD 
found thiopurines to be effective in maintaining remis-
sion with higher doses of  AZA appearing more effec-
tive than lower dosages[22]. The SONIC trial found that 
steroid free clinical remission was achieved in only 30% 
and 24% at 26 and 52 wk respectively for patients receiv-
ing thiopurine monotherapy[16]. Furthermore, a trial of  
63 patients aged 15-65 years found that 42% of  patients 
receiving thiopurines vs 7% receiving placebo remained 
in remission 15 mo after thiopurine initiation[5].
For our study, variation in practitioner practice pat-
terns could have impacted outcomes. The mean dose at 
thiopurine initiation for included patients was less than 
recommended dosing (< 1.0 mg/kg per day) suggesting 
the relative decreased SFR for this cohort could relate 
to inadequate dosing rather than medication ineffec-
tiveness. The use of  quality improvement methods in 
pediatric IBD to impact clinical outcomes by delivering 
more consistent care, including with regard to thiopu-
rine dosing, has been previously described[18]. Metabo-
lite measurement for this cohort was also variable with 
< 50% of  included patients having metabolites ob-
tained. This failure to optimize thiopurine dosing may 
also have contributed to the reduced maintenance of  
remission[23].
Additional limitations of  our study common to all 
studies utilizing registry data include patients lost to 
follow-up and inability to account for missing data. Fur-
thermore, the impact of  medication adherence upon 
outcomes was not captured and therefore could not be 
evaluated. Previous studies evaluating adherence in pe-
diatric IBD have found that nearly 40% of  thiopurine 
doses may be missed[24,25]. The use of  PGA as our study 
outcome also allowed for variation in practitioner as-
sessment of  clinical remission vs active disease. Finally, 
the number of  patients who met inclusion criteria was 
somewhat limited.
However, despite the limitations described, it is rec-
ognized that variable thiopurine dosing, metabolite mea-
surement by practitioners, and imperfect adherence by 
patients is a clinical reality. Thus, we believe that our re-
sults reflect clinical effectiveness of  thiopurines in actual 
practice. A more structured approach to care, including 
more consistent thiopurine dosing and potentially me-
tabolite testing may improve clinical outcomes.
In conclusion, the use of  thiopurines by practicing 
clinicians was effective for some pediatric patients with 
CD in maintaining clinical remission. However, treat-
ment failure within 12 mo of  achieving remission was 
common for this cohort of  patients. A more consistent 
approach to thiopurine dosing and metabolite measure-
ment may improve clinical outcomes.
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Thiopurines to maintain remission for pediatric Crohn’s disease (CD) have had 
variable effectiveness. This manuscript describes the prospective observational 
outcomes for a cohort of patients in maintaining remission with thiopurines.
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Research frontiers
The effectiveness of thiopurines in maintaining remission in pediatric CD may 
be less than might have been predicted by the results of the initial random-
ized control study. This real world cohort found variable approaches to the 
use of thiopurines among practitioners regarding dosing and metabolite mea-
surement. 
Innovations and breakthroughs
The results of this study are more similar to subsequent pediatric studies and to 
more recent adult studies evaluating the use of thiopurines in the treatment of 
CD. The variable approach to dosing and metabolite measurement could have 
impacted in the poorer outcomes that were found.
Applications
The study suggests thiopurines may be less effective in maintaining remission 
for pediatric CD than previously described. The impact of optimization of the 
thiopurines through more standardized dosing and metabolite measurement 
could be further explored.
Terminology
The term thiopurines refers to the medications mercaptopurine and azathiopu-
rine that are commonly used therapies for treatment of pediatric CD.
Peer review
This multi-center, prospective observational study suggests the real world use of 
thiopurines may be less effective in maintaining remission for pediatric Crohn’s 
disease than might have been predicted by the initial randomized controlled trial.
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